Identification

Name
Mevastatin
Accession Number
DB06693
Type
Small Molecule
Groups
Experimental
Description

Mevastatin or compactin is a cholesterol-lowering agent isolated from Penicillium citinium. It was the first discovered agent belonging to the class of cholesterol-lowering medications known as statins. During a search for antibiotic compounds produced by fungi in 1971, Akira Endo at Sankyo Co. (Japan) discovered a class of compounds that appeared to lower plasma cholesterol levels. Two years later, the research group isolated a compound structurally similar to hydroxymethylglutarate (HMG) that inhibited the incorporation of acetate. The compound was proposed to bind to the reductase enzyme and was named compactin. Mevastatin is a competitive inhibitor of HMG-Coenzyme A (HMG-CoA) reductase with a binding affinity 10,000 times greater than the HMG-CoA substrate itself. Mevastatin is a pro-drug that is activated by in vivo hydrolysis of the lactone ring. It has served as one of the lead compounds for the development of the synthetic compounds used today.

Structure
Thumb
Synonyms
  • Mevastatina
  • Mévastatine
  • mevastatinum
External IDs
Antibiotic ML 236B / CS 500 / ML 236 B / ML-236B
International/Other Brands
Compactin
Categories
UNII
1UQM1K0W9X
CAS number
73573-88-3
Weight
Average: 390.52
Monoisotopic: 390.240624195
Chemical Formula
C23H34O5
InChI Key
AJLFOPYRIVGYMJ-INTXDZFKSA-N
InChI
InChI=1S/C23H34O5/c1-4-14(2)23(26)28-20-7-5-6-16-9-8-15(3)19(22(16)20)11-10-18-12-17(24)13-21(25)27-18/h6,8-9,14-15,17-20,22,24H,4-5,7,10-13H2,1-3H3/t14-,15-,17+,18+,19-,20-,22-/m0/s1
IUPAC Name
(1S,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl}-7-methyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl (2S)-2-methylbutanoate
SMILES

Pharmacology

Indication

Not used therapeutically due to its many side effects.

Structured Indications
Not Available
Pharmacodynamics

The primary cause of cardiovascular disease is atherosclerotic plaque formation. Sustained elevations of cholesterol in the blood increase the risk of cardiovascular disease. Mevastatin lowers hepatic production of cholesterol by competitively inhibiting HMG-CoA reductase, the enzyme that catalyzes the rate-limiting step in the cholesterol biosynthesis pathway via the mevalonic acid pathway. Decreased hepatic cholesterol levels causes increased uptake of low density lipoprotein (LDL) cholesterol and reduces cholesterol levels in the circulation.

Mechanism of action

Mevastatin is structurally similar to the HMG, a substituent of the endogenous substrate of HMG-CoA reductase. Mevastatin is a prodrug that is activated in vivo via hydrolysis of the lactone ring. The hydrolyzed lactone ring mimics the tetrahedral intermediate produced by the reductase allowing the agent to bind with 10,000 times greater affinity than its natural substrate. The bicyclic portion of mevastatin binds to the coenzyme A portion of the active site.

TargetActionsOrganism
A3-hydroxy-3-methylglutaryl-coenzyme A reductase
inhibitor
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

Side effects include those of other statins, such as myalgias, abdominal pain, nausea. It also has a higher chance of giving more severe side effects related to myotoxicity (myopathy, myositis, rhabdomyolysis), and hepatotoxicity, than other statins. Due to these major side effects and their enhanced rate of occurance, Mevastatin is not given therapeutically.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AbafunginThe risk or severity of adverse effects can be increased when Abafungin is combined with Mevastatin.Investigational
AcenocoumarolMevastatin may increase the anticoagulant activities of Acenocoumarol.Approved
AcetaminophenThe serum concentration of Mevastatin can be increased when it is combined with Acetaminophen.Approved
AcetazolamideThe serum concentration of Mevastatin can be increased when it is combined with Acetazolamide.Approved, Vet Approved
AcipimoxAcipimox may increase the myopathic rhabdomyolysis activities of Mevastatin.Approved, Investigational
AlbaconazoleThe risk or severity of adverse effects can be increased when Albaconazole is combined with Mevastatin.Investigational
AldesleukinThe serum concentration of Mevastatin can be increased when it is combined with Aldesleukin.Approved
AlmasilateThe serum concentration of Mevastatin can be decreased when it is combined with Almasilate.Approved, Experimental
AloglutamolThe serum concentration of Mevastatin can be decreased when it is combined with Aloglutamol.Experimental
AlprazolamThe serum concentration of Mevastatin can be increased when it is combined with Alprazolam.Approved, Illicit, Investigational
AluminiumThe serum concentration of Mevastatin can be decreased when it is combined with Aluminium.Approved
Aluminium acetoacetateThe serum concentration of Mevastatin can be decreased when it is combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe serum concentration of Mevastatin can be decreased when it is combined with Aluminium glycinate.Experimental
Aluminum hydroxideThe serum concentration of Mevastatin can be decreased when it is combined with Aluminum hydroxide.Approved
AmbroxolThe serum concentration of Mevastatin can be increased when it is combined with Ambroxol.Approved, Investigational
AmiodaroneThe metabolism of Mevastatin can be decreased when combined with Amiodarone.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Mevastatin is combined with Amlodipine.Approved
Amphotericin BThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Mevastatin.Approved, Investigational
AmprenavirThe serum concentration of Mevastatin can be increased when it is combined with Amprenavir.Approved
AmrinoneThe risk or severity of adverse effects can be increased when Mevastatin is combined with Amrinone.Approved
AnastrozoleThe serum concentration of Mevastatin can be increased when it is combined with Anastrozole.Approved, Investigational
AntipyrineThe serum concentration of Mevastatin can be increased when it is combined with Antipyrine.Approved
AprepitantThe serum concentration of Mevastatin can be increased when it is combined with Aprepitant.Approved, Investigational
Arsenic trioxideThe serum concentration of Mevastatin can be increased when it is combined with Arsenic trioxide.Approved, Investigational
AstemizoleThe serum concentration of Mevastatin can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe serum concentration of Mevastatin can be increased when it is combined with Atazanavir.Approved, Investigational
AtomoxetineThe serum concentration of Mevastatin can be increased when it is combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Mevastatin can be increased when it is combined with Atorvastatin.Approved
AzelastineThe serum concentration of Mevastatin can be increased when it is combined with Azelastine.Approved
AzelnidipineThe risk or severity of adverse effects can be increased when Mevastatin is combined with Azelnidipine.Approved, Investigational
AzimilideThe risk or severity of adverse effects can be increased when Mevastatin is combined with Azimilide.Investigational
AzithromycinThe serum concentration of Mevastatin can be increased when it is combined with Azithromycin.Approved
BarnidipineThe risk or severity of adverse effects can be increased when Mevastatin is combined with Barnidipine.Approved
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Mevastatin.Investigational
BencyclaneThe risk or severity of adverse effects can be increased when Mevastatin is combined with Bencyclane.Experimental
BenidipineThe risk or severity of adverse effects can be increased when Mevastatin is combined with Benidipine.Approved, Investigational
BepridilThe risk or severity of adverse effects can be increased when Mevastatin is combined with Bepridil.Approved, Withdrawn
BetamethasoneThe serum concentration of Mevastatin can be increased when it is combined with Betamethasone.Approved, Vet Approved
BezafibrateBezafibrate may increase the myopathic rhabdomyolysis activities of Mevastatin.Approved
BicalutamideThe serum concentration of Mevastatin can be increased when it is combined with Bicalutamide.Approved
BifonazoleThe serum concentration of Mevastatin can be increased when it is combined with Bifonazole.Approved, Investigational
Bismuth SubcitrateThe serum concentration of Mevastatin can be decreased when it is combined with Bismuth Subcitrate.Approved
Bismuth subnitrateThe serum concentration of Mevastatin can be decreased when it is combined with Bismuth subnitrate.Experimental
BoceprevirThe serum concentration of Mevastatin can be increased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe serum concentration of Mevastatin can be increased when it is combined with Bortezomib.Approved, Investigational
BosentanThe metabolism of Mevastatin can be increased when combined with Bosentan.Approved, Investigational
Brentuximab vedotinThe serum concentration of Mevastatin can be increased when it is combined with Brentuximab vedotin.Approved
BromocriptineThe serum concentration of Mevastatin can be increased when it is combined with Bromocriptine.Approved, Investigational
BuprenorphineThe serum concentration of Mevastatin can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe metabolism of Buspirone can be decreased when combined with Mevastatin.Approved, Investigational
BusulfanThe serum concentration of Busulfan can be increased when it is combined with Mevastatin.Approved, Investigational
ButoconazoleThe risk or severity of adverse effects can be increased when Butoconazole is combined with Mevastatin.Approved
CabergolineThe serum concentration of Mevastatin can be increased when it is combined with Cabergoline.Approved
CaffeineThe serum concentration of Mevastatin can be increased when it is combined with Caffeine.Approved
Calcium CarbonateThe serum concentration of Mevastatin can be decreased when it is combined with Calcium Carbonate.Approved
Calcium silicateThe serum concentration of Mevastatin can be decreased when it is combined with Calcium silicate.Experimental
CapsaicinThe serum concentration of Mevastatin can be increased when it is combined with Capsaicin.Approved
CarbomycinThe risk or severity of adverse effects can be increased when Carbomycin is combined with Mevastatin.Vet Approved
CarboxyamidotriazoleThe risk or severity of adverse effects can be increased when Mevastatin is combined with Carboxyamidotriazole.Investigational
CaroverineThe risk or severity of adverse effects can be increased when Mevastatin is combined with Caroverine.Experimental
CaspofunginThe serum concentration of Mevastatin can be increased when it is combined with Caspofungin.Approved
CeritinibThe serum concentration of Mevastatin can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Mevastatin can be increased when it is combined with Cerivastatin.Withdrawn
ChloramphenicolThe serum concentration of Mevastatin can be increased when it is combined with Chloramphenicol.Approved, Vet Approved
ChlorzoxazoneThe serum concentration of Mevastatin can be increased when it is combined with Chlorzoxazone.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Mevastatin is combined with Cilnidipine.Approved, Investigational
CilostazolThe serum concentration of Mevastatin can be increased when it is combined with Cilostazol.Approved
CimetidineThe serum concentration of Mevastatin can be increased when it is combined with Cimetidine.Approved
CinnarizineThe risk or severity of adverse effects can be increased when Mevastatin is combined with Cinnarizine.Approved, Investigational
CiprofibrateThe risk or severity of adverse effects can be increased when Ciprofibrate is combined with Mevastatin.Approved, Investigational
CiprofloxacinThe serum concentration of Mevastatin can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Mevastatin.Approved, Investigational, Withdrawn
ClarithromycinThe serum concentration of Mevastatin can be increased when it is combined with Clarithromycin.Approved
ClemastineThe serum concentration of Mevastatin can be increased when it is combined with Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Mevastatin is combined with Clevidipine.Approved
ClindamycinThe serum concentration of Mevastatin can be increased when it is combined with Clindamycin.Approved, Vet Approved
ClofazimineThe serum concentration of Mevastatin can be increased when it is combined with Clofazimine.Approved, Investigational
ClomifeneThe serum concentration of Mevastatin can be increased when it is combined with Clomifene.Approved, Investigational
ClorindioneMevastatin may increase the anticoagulant activities of Clorindione.Experimental
ClotiazepamThe serum concentration of Mevastatin can be increased when it is combined with Clotiazepam.Approved, Illicit
ClotrimazoleThe serum concentration of Mevastatin can be increased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Mevastatin can be increased when it is combined with Clozapine.Approved
CobicistatThe serum concentration of Mevastatin can be increased when it is combined with Cobicistat.Approved
CocaineThe serum concentration of Mevastatin can be increased when it is combined with Cocaine.Approved, Illicit
ColchicineColchicine may increase the myopathic rhabdomyolysis activities of Mevastatin.Approved
ConivaptanThe metabolism of Conivaptan can be decreased when combined with Mevastatin.Approved, Investigational
Cortisone acetateThe serum concentration of Mevastatin can be increased when it is combined with Cortisone acetate.Approved
CrizotinibThe serum concentration of Mevastatin can be increased when it is combined with Crizotinib.Approved
CyclophosphamideThe serum concentration of Mevastatin can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe metabolism of Cyclosporine can be decreased when combined with Mevastatin.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Mevastatin can be increased when it is combined with Cyproterone acetate.Approved, Investigational
DaclatasvirThe serum concentration of Mevastatin can be increased when it is combined with Daclatasvir.Approved
DalfopristinThe serum concentration of Mevastatin can be increased when it is combined with Dalfopristin.Approved
DanazolThe serum concentration of Mevastatin can be increased when it is combined with Danazol.Approved
DaptomycinThe risk or severity of adverse effects can be increased when Mevastatin is combined with Daptomycin.Approved, Investigational
DarodipineThe risk or severity of adverse effects can be increased when Mevastatin is combined with Darodipine.Experimental
DarunavirThe serum concentration of Mevastatin can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Mevastatin can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Mevastatin can be increased when it is combined with Daunorubicin.Approved
DelavirdineThe serum concentration of Mevastatin can be increased when it is combined with Delavirdine.Approved
DesipramineThe serum concentration of Mevastatin can be increased when it is combined with Desipramine.Approved
DexamethasoneThe serum concentration of Mevastatin can be increased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DextropropoxypheneThe serum concentration of Mevastatin can be increased when it is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DiazepamThe serum concentration of Mevastatin can be increased when it is combined with Diazepam.Approved, Illicit, Vet Approved
DicoumarolMevastatin may increase the anticoagulant activities of Dicoumarol.Approved
DidanosineDidanosine can cause a decrease in the absorption of Mevastatin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DiethylstilbestrolThe serum concentration of Mevastatin can be increased when it is combined with Diethylstilbestrol.Approved, Investigational
DihydroergotamineThe serum concentration of Mevastatin can be increased when it is combined with Dihydroergotamine.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Mevastatin is combined with Diltiazem.Approved
Dimethyl sulfoxideThe serum concentration of Mevastatin can be increased when it is combined with Dimethyl sulfoxide.Approved, Vet Approved
DiphenadioneMevastatin may increase the anticoagulant activities of Diphenadione.Experimental
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Mevastatin.Approved, Investigational
DofetilideThe metabolism of Dofetilide can be decreased when combined with Mevastatin.Approved
DotarizineThe risk or severity of adverse effects can be increased when Mevastatin is combined with Dotarizine.Investigational
DoxorubicinThe serum concentration of Mevastatin can be increased when it is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe serum concentration of Mevastatin can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe serum concentration of Mevastatin can be increased when it is combined with Dronedarone.Approved
EconazoleThe serum concentration of Mevastatin can be increased when it is combined with Econazole.Approved
EfavirenzThe serum concentration of Mevastatin can be increased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe risk or severity of adverse effects can be increased when Efinaconazole is combined with Mevastatin.Approved
EfonidipineThe risk or severity of adverse effects can be increased when Mevastatin is combined with Efonidipine.Approved, Investigational
ElbasvirThe serum concentration of Mevastatin can be increased when it is combined with Elbasvir.Approved
EnasidenibThe serum concentration of Mevastatin can be increased when it is combined with Enasidenib.Approved
EperisoneThe risk or severity of adverse effects can be increased when Mevastatin is combined with Eperisone.Approved, Investigational
EpinephrineThe serum concentration of Mevastatin can be increased when it is combined with Epinephrine.Approved, Vet Approved
Ergoloid mesylateThe serum concentration of Mevastatin can be increased when it is combined with Ergoloid mesylate.Approved
ErgonovineThe serum concentration of Mevastatin can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Mevastatin can be increased when it is combined with Ergotamine.Approved
ErythromycinThe serum concentration of Mevastatin can be increased when it is combined with Erythromycin.Approved, Vet Approved
EthanolThe serum concentration of Mevastatin can be increased when it is combined with Ethanol.Approved
Ethyl biscoumacetateMevastatin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtoposideThe serum concentration of Mevastatin can be increased when it is combined with Etoposide.Approved
EtoricoxibThe serum concentration of Mevastatin can be increased when it is combined with Etoricoxib.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be increased when it is combined with Mevastatin.Approved
EzetimibeThe serum concentration of Mevastatin can be increased when it is combined with Ezetimibe.Approved
FelodipineThe risk or severity of adverse effects can be increased when Mevastatin is combined with Felodipine.Approved, Investigational
FendilineThe risk or severity of adverse effects can be increased when Mevastatin is combined with Fendiline.Withdrawn
FenofibrateThe risk or severity of adverse effects can be increased when Fenofibrate is combined with Mevastatin.Approved
FentanylThe serum concentration of Mevastatin can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenticonazoleThe risk or severity of adverse effects can be increased when Fenticonazole is combined with Mevastatin.Experimental
FidaxomicinThe risk or severity of adverse effects can be increased when Fidaxomicin is combined with Mevastatin.Approved
FluconazoleThe serum concentration of Mevastatin can be increased when it is combined with Fluconazole.Approved
FluindioneMevastatin may increase the anticoagulant activities of Fluindione.Investigational
FlunarizineThe risk or severity of adverse effects can be increased when Mevastatin is combined with Flunarizine.Approved
FluoxetineThe serum concentration of Mevastatin can be increased when it is combined with Fluoxetine.Approved, Vet Approved
Fluticasone propionateThe serum concentration of Mevastatin can be increased when it is combined with Fluticasone propionate.Approved
FluvastatinThe serum concentration of Mevastatin can be increased when it is combined with Fluvastatin.Approved
FluvoxamineThe serum concentration of Mevastatin can be increased when it is combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe serum concentration of Mevastatin can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Mevastatin can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Mevastatin can be decreased when it is combined with Fosphenytoin.Approved
Fusidic AcidThe risk or severity of adverse effects can be increased when Fusidic Acid is combined with Mevastatin.Approved
GabapentinThe risk or severity of adverse effects can be increased when Mevastatin is combined with Gabapentin.Approved, Investigational
GallopamilThe risk or severity of adverse effects can be increased when Mevastatin is combined with Gallopamil.Investigational
GemfibrozilThe serum concentration of Mevastatin can be increased when it is combined with Gemfibrozil.Approved
GlyburideThe serum concentration of Mevastatin can be increased when it is combined with Glyburide.Approved
Glycerol PhenylbutyrateThe serum concentration of Mevastatin can be increased when it is combined with Glycerol Phenylbutyrate.Approved
HaloperidolThe serum concentration of Mevastatin can be increased when it is combined with Haloperidol.Approved
HistamineThe serum concentration of Mevastatin can be increased when it is combined with Histamine.Approved, Investigational
HydralazineThe serum concentration of Mevastatin can be increased when it is combined with Hydralazine.Approved
HydrocortisoneThe serum concentration of Mevastatin can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
HydrotalciteThe serum concentration of Mevastatin can be decreased when it is combined with Hydrotalcite.Experimental, Investigational
IdelalisibThe serum concentration of Mevastatin can be increased when it is combined with Idelalisib.Approved
IfosfamideThe serum concentration of Mevastatin can be increased when it is combined with Ifosfamide.Approved
IloperidoneThe serum concentration of Mevastatin can be increased when it is combined with Iloperidone.Approved
ImatinibThe serum concentration of Mevastatin can be increased when it is combined with Imatinib.Approved
IndinavirThe serum concentration of Mevastatin can be increased when it is combined with Indinavir.Approved
indisulamThe serum concentration of Mevastatin can be increased when it is combined with indisulam.Investigational
IrbesartanThe serum concentration of Mevastatin can be increased when it is combined with Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of Mevastatin can be increased when it is combined with Irinotecan.Approved, Investigational
IsavuconazoleThe risk or severity of adverse effects can be increased when Isavuconazole is combined with Mevastatin.Approved, Investigational
IsavuconazoniumThe serum concentration of Mevastatin can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsoconazoleThe risk or severity of adverse effects can be increased when Isoconazole is combined with Mevastatin.Approved
IsoniazidThe serum concentration of Mevastatin can be increased when it is combined with Isoniazid.Approved
IsradipineThe risk or severity of adverse effects can be increased when Mevastatin is combined with Isradipine.Approved
ItraconazoleThe serum concentration of Mevastatin can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Mevastatin can be increased when it is combined with Ivacaftor.Approved
JosamycinThe serum concentration of Mevastatin can be increased when it is combined with Josamycin.Approved, Investigational
KetazolamThe serum concentration of Mevastatin can be increased when it is combined with Ketazolam.Approved
KetoconazoleThe serum concentration of Mevastatin can be increased when it is combined with Ketoconazole.Approved, Investigational
KitasamycinThe risk or severity of adverse effects can be increased when Kitasamycin is combined with Mevastatin.Experimental
LacidipineThe risk or severity of adverse effects can be increased when Mevastatin is combined with Lacidipine.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Mevastatin is combined with Lamotrigine.Approved, Investigational
LansoprazoleThe serum concentration of Mevastatin can be increased when it is combined with Lansoprazole.Approved, Investigational
Lanthanum carbonateThe serum concentration of Lanthanum carbonate can be decreased when it is combined with Mevastatin.Approved
LapatinibThe serum concentration of Mevastatin can be increased when it is combined with Lapatinib.Approved, Investigational
LercanidipineThe risk or severity of adverse effects can be increased when Mevastatin is combined with Lercanidipine.Approved, Investigational
LevofloxacinThe serum concentration of Mevastatin can be increased when it is combined with Levofloxacin.Approved, Investigational
LevosalbutamolThe serum concentration of Mevastatin can be increased when it is combined with Levosalbutamol.Approved
LidocaineThe serum concentration of Mevastatin can be increased when it is combined with Lidocaine.Approved, Vet Approved
LidoflazineThe risk or severity of adverse effects can be increased when Mevastatin is combined with Lidoflazine.Experimental
LinagliptinThe serum concentration of Mevastatin can be increased when it is combined with Linagliptin.Approved
LomitapideThe serum concentration of Mevastatin can be increased when it is combined with Lomitapide.Approved
LomustineThe serum concentration of Mevastatin can be increased when it is combined with Lomustine.Approved
LopinavirThe serum concentration of Mevastatin can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Mevastatin can be increased when it is combined with Loratadine.Approved
LosartanThe metabolism of Losartan can be decreased when combined with Mevastatin.Approved
LovastatinThe serum concentration of Mevastatin can be increased when it is combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Mevastatin can be increased when it is combined with Luliconazole.Approved
LurasidoneThe serum concentration of Mevastatin can be increased when it is combined with Lurasidone.Approved
MagaldrateThe serum concentration of Mevastatin can be decreased when it is combined with Magaldrate.Approved, Withdrawn
Magnesium HydroxideThe serum concentration of Mevastatin can be decreased when it is combined with Magnesium Hydroxide.Approved
Magnesium oxideThe serum concentration of Mevastatin can be decreased when it is combined with Magnesium oxide.Approved
Magnesium peroxideThe serum concentration of Mevastatin can be decreased when it is combined with Magnesium peroxide.Experimental
Magnesium silicateThe serum concentration of Mevastatin can be decreased when it is combined with Magnesium silicate.Approved, Experimental
Magnesium SulfateThe risk or severity of adverse effects can be increased when Mevastatin is combined with Magnesium Sulfate.Approved, Vet Approved
Magnesium TrisilicateThe serum concentration of Mevastatin can be decreased when it is combined with Magnesium Trisilicate.Approved
ManidipineThe risk or severity of adverse effects can be increased when Mevastatin is combined with Manidipine.Approved, Investigational
MefloquineThe serum concentration of Mevastatin can be increased when it is combined with Mefloquine.Approved
MequitazineThe serum concentration of Mevastatin can be increased when it is combined with Mequitazine.Approved
MethadoneThe serum concentration of Mevastatin can be increased when it is combined with Methadone.Approved
MethazolamideThe serum concentration of Mevastatin can be increased when it is combined with Methazolamide.Approved
MethimazoleThe serum concentration of Mevastatin can be increased when it is combined with Methimazole.Approved
MethylergometrineThe serum concentration of Mevastatin can be increased when it is combined with Methylergometrine.Approved
MethylprednisoloneThe serum concentration of Mevastatin can be increased when it is combined with Methylprednisolone.Approved, Vet Approved
MetronidazoleThe serum concentration of Mevastatin can be increased when it is combined with Metronidazole.Approved
MetyraponeThe serum concentration of Mevastatin can be increased when it is combined with Metyrapone.Approved
MibefradilThe risk or severity of adverse effects can be increased when Mevastatin is combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe serum concentration of Mevastatin can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Mevastatin can be increased when it is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Mevastatin can be increased when it is combined with Mifepristone.Approved, Investigational
MirtazapineThe serum concentration of Mevastatin can be increased when it is combined with Mirtazapine.Approved
MitoxantroneThe serum concentration of Mevastatin can be increased when it is combined with Mitoxantrone.Approved, Investigational
ModafinilThe serum concentration of Mevastatin can be increased when it is combined with Modafinil.Approved, Investigational
NaftopidilThe risk or severity of adverse effects can be increased when Mevastatin is combined with Naftopidil.Investigational
NefazodoneThe serum concentration of Mevastatin can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Mevastatin can be increased when it is combined with Nelfinavir.Approved
NetupitantThe serum concentration of Mevastatin can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Mevastatin can be increased when it is combined with Nevirapine.Approved
NiacinThe risk or severity of adverse effects can be increased when Niacin is combined with Mevastatin.Approved, Investigational, Nutraceutical
NicardipineThe risk or severity of adverse effects can be increased when Mevastatin is combined with Nicardipine.Approved
NicotinamideThe risk or severity of adverse effects can be increased when Nicotinamide is combined with Mevastatin.Approved
NifedipineThe risk or severity of adverse effects can be increased when Mevastatin is combined with Nifedipine.Approved
NiguldipineThe risk or severity of adverse effects can be increased when Mevastatin is combined with Niguldipine.Experimental
NilotinibThe serum concentration of Mevastatin can be increased when it is combined with Nilotinib.Approved, Investigational
NiludipineThe risk or severity of adverse effects can be increased when Mevastatin is combined with Niludipine.Experimental
NilvadipineThe risk or severity of adverse effects can be increased when Mevastatin is combined with Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Mevastatin is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Mevastatin is combined with Nimodipine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Mevastatin is combined with Nisoldipine.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Mevastatin is combined with Nitrendipine.Approved, Investigational
Nitric OxideThe serum concentration of Mevastatin can be increased when it is combined with Nitric Oxide.Approved
NorfloxacinThe serum concentration of Mevastatin can be increased when it is combined with Norfloxacin.Approved
NoscapineThe serum concentration of Mevastatin can be increased when it is combined with Noscapine.Investigational
OlanzapineThe serum concentration of Mevastatin can be increased when it is combined with Olanzapine.Approved, Investigational
OlaparibThe serum concentration of Mevastatin can be increased when it is combined with Olaparib.Approved
OleandomycinThe risk or severity of adverse effects can be increased when Oleandomycin is combined with Mevastatin.Vet Approved
OmeprazoleThe serum concentration of Mevastatin can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OmoconazoleThe risk or severity of adverse effects can be increased when Omoconazole is combined with Mevastatin.Experimental
OtiloniumThe risk or severity of adverse effects can be increased when Mevastatin is combined with Otilonium.Experimental, Investigational
OxiconazoleThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Mevastatin.Approved
OxybutyninThe serum concentration of Mevastatin can be increased when it is combined with Oxybutynin.Approved, Investigational
OxymetholoneThe serum concentration of Mevastatin can be increased when it is combined with Oxymetholone.Approved, Illicit
PaclitaxelThe serum concentration of Mevastatin can be increased when it is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Mevastatin can be increased when it is combined with Palbociclib.Approved
ParamethasoneThe serum concentration of Mevastatin can be increased when it is combined with Paramethasone.Approved
PazopanibMevastatin may increase the hepatotoxic activities of Pazopanib.Approved
PergolideThe serum concentration of Mevastatin can be increased when it is combined with Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerhexilineThe risk or severity of adverse effects can be increased when Mevastatin is combined with Perhexiline.Approved, Investigational
PhenelzineThe serum concentration of Mevastatin can be increased when it is combined with Phenelzine.Approved
PhenindioneMevastatin may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonMevastatin may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Mevastatin.Approved, Vet Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Mevastatin.Approved
PilocarpineThe serum concentration of Mevastatin can be increased when it is combined with Pilocarpine.Approved
PimozideMevastatin may increase the arrhythmogenic activities of Pimozide.Approved
PinaveriumThe risk or severity of adverse effects can be increased when Mevastatin is combined with Pinaverium.Approved
PosaconazoleThe serum concentration of Mevastatin can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PravastatinThe serum concentration of Mevastatin can be increased when it is combined with Pravastatin.Approved
PrednisoloneThe serum concentration of Mevastatin can be increased when it is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe serum concentration of Mevastatin can be increased when it is combined with Prednisone.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Mevastatin is combined with Pregabalin.Approved, Illicit, Investigational
PrenylamineThe risk or severity of adverse effects can be increased when Mevastatin is combined with Prenylamine.Withdrawn
PrimaquineThe serum concentration of Mevastatin can be increased when it is combined with Primaquine.Approved
ProgesteroneThe therapeutic efficacy of Progesterone can be decreased when used in combination with Mevastatin.Approved, Vet Approved
PropofolThe serum concentration of Mevastatin can be increased when it is combined with Propofol.Approved, Investigational, Vet Approved
QuinidineThe metabolism of Quinidine can be decreased when combined with Mevastatin.Approved
QuinineThe serum concentration of Mevastatin can be increased when it is combined with Quinine.Approved
QuinupristinThe serum concentration of Mevastatin can be increased when it is combined with Quinupristin.Approved
RabeprazoleThe serum concentration of Mevastatin can be increased when it is combined with Rabeprazole.Approved, Investigational
RaloxifeneThe serum concentration of Mevastatin can be increased when it is combined with Raloxifene.Approved, Investigational
RaltegravirRaltegravir may increase the myopathic rhabdomyolysis activities of Mevastatin.Approved
RanitidineThe serum concentration of Mevastatin can be increased when it is combined with Ranitidine.Approved
RanolazineThe metabolism of Ranolazine can be decreased when combined with Mevastatin.Approved, Investigational
RavuconazoleThe risk or severity of adverse effects can be increased when Ravuconazole is combined with Mevastatin.Investigational
RegorafenibThe serum concentration of Mevastatin can be increased when it is combined with Regorafenib.Approved
RepaglinideThe serum concentration of Mevastatin can be increased when it is combined with Repaglinide.Approved, Investigational
ResveratrolThe serum concentration of Mevastatin can be increased when it is combined with Resveratrol.Approved, Experimental, Investigational
RifabutinThe serum concentration of Mevastatin can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Mevastatin can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Mevastatin can be decreased when it is combined with Rifapentine.Approved
RifaximinThe serum concentration of Mevastatin can be decreased when it is combined with Rifaximin.Approved, Investigational
RilpivirineThe serum concentration of Mevastatin can be increased when it is combined with Rilpivirine.Approved
RisedronateThe risk or severity of adverse effects can be increased when Mevastatin is combined with Risedronate.Approved, Investigational
RisperidoneThe serum concentration of Mevastatin can be increased when it is combined with Risperidone.Approved, Investigational
RitonavirThe serum concentration of Mevastatin can be increased when it is combined with Ritonavir.Approved, Investigational
RivastigmineThe serum concentration of Mevastatin can be increased when it is combined with Rivastigmine.Approved, Investigational
RolitetracyclineThe serum concentration of Mevastatin can be increased when it is combined with Rolitetracycline.Approved
RosuvastatinThe serum concentration of Mevastatin can be increased when it is combined with Rosuvastatin.Approved
RoxithromycinThe serum concentration of Mevastatin can be increased when it is combined with Roxithromycin.Approved, Investigational, Withdrawn
RucaparibThe serum concentration of Mevastatin can be increased when it is combined with Rucaparib.Approved, Investigational
RutinThe serum concentration of Mevastatin can be increased when it is combined with Rutin.Experimental, Investigational
SalbutamolThe serum concentration of Mevastatin can be increased when it is combined with Salbutamol.Approved, Vet Approved
SaquinavirThe serum concentration of Mevastatin can be increased when it is combined with Saquinavir.Approved, Investigational
SarilumabThe serum concentration of Mevastatin can be increased when it is combined with Sarilumab.Approved
SertaconazoleThe risk or severity of adverse effects can be increased when Sertaconazole is combined with Mevastatin.Approved
SertralineThe serum concentration of Mevastatin can be increased when it is combined with Sertraline.Approved
SildenafilThe serum concentration of Mevastatin can be increased when it is combined with Sildenafil.Approved, Investigational
SimeprevirThe serum concentration of Mevastatin can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Mevastatin can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Mevastatin can be increased when it is combined with Sirolimus.Approved, Investigational
SitaxentanThe serum concentration of Mevastatin can be increased when it is combined with Sitaxentan.Approved, Investigational, Withdrawn
Sodium bicarbonateThe serum concentration of Mevastatin can be decreased when it is combined with Sodium bicarbonate.Approved
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Mevastatin.Approved
SolithromycinThe risk or severity of adverse effects can be increased when Solithromycin is combined with Mevastatin.Investigational
SorafenibThe serum concentration of Mevastatin can be increased when it is combined with Sorafenib.Approved, Investigational
SpiramycinThe risk or severity of adverse effects can be increased when Spiramycin is combined with Mevastatin.Approved
St. John's WortThe metabolism of Mevastatin can be increased when combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Mevastatin can be increased when it is combined with Stiripentol.Approved
SucralfateSucralfate can cause a decrease in the absorption of Mevastatin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SulconazoleThe risk or severity of adverse effects can be increased when Sulconazole is combined with Mevastatin.Approved
SulfamethoxazoleThe serum concentration of Mevastatin can be increased when it is combined with Sulfamethoxazole.Approved
SulfanilamideThe serum concentration of Mevastatin can be increased when it is combined with Sulfanilamide.Approved
SulfinpyrazoneThe serum concentration of Mevastatin can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe serum concentration of Mevastatin can be increased when it is combined with Sulfisoxazole.Approved, Vet Approved
SunitinibThe metabolism of Sunitinib can be decreased when combined with Mevastatin.Approved, Investigational
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Mevastatin.Approved, Investigational
TadalafilThe serum concentration of Mevastatin can be increased when it is combined with Tadalafil.Approved, Investigational
TamoxifenThe serum concentration of Mevastatin can be increased when it is combined with Tamoxifen.Approved
TelaprevirThe serum concentration of Mevastatin can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelithromycinThe serum concentration of Mevastatin can be increased when it is combined with Telithromycin.Approved
TemsirolimusThe serum concentration of Mevastatin can be increased when it is combined with Temsirolimus.Approved
TeniposideThe serum concentration of Mevastatin can be increased when it is combined with Teniposide.Approved
TerconazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Mevastatin.Approved
TerfenadineThe serum concentration of Mevastatin can be increased when it is combined with Terfenadine.Withdrawn
TerodilineThe risk or severity of adverse effects can be increased when Mevastatin is combined with Terodiline.Experimental
TesmilifeneThe serum concentration of Mevastatin can be increased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Mevastatin can be increased when it is combined with Testosterone.Approved, Investigational
TetracyclineThe serum concentration of Mevastatin can be increased when it is combined with Tetracycline.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Mevastatin is combined with Tetrahydropalmatine.Investigational
ThiopentalThe serum concentration of Mevastatin can be increased when it is combined with Thiopental.Approved, Vet Approved
TicagrelorThe serum concentration of Mevastatin can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe serum concentration of Mevastatin can be increased when it is combined with Ticlopidine.Approved
TioclomarolMevastatin may increase the anticoagulant activities of Tioclomarol.Experimental
TioconazoleThe serum concentration of Mevastatin can be increased when it is combined with Tioconazole.Approved
TipranavirThe serum concentration of Mevastatin can be increased when it is combined with Tipranavir.Approved, Investigational
TofisopamThe serum concentration of Mevastatin can be increased when it is combined with Tofisopam.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Mevastatin is combined with Tolfenamic Acid.Approved
TopiroxostatThe serum concentration of Mevastatin can be increased when it is combined with Topiroxostat.Approved, Investigational
TopotecanThe serum concentration of Mevastatin can be increased when it is combined with Topotecan.Approved, Investigational
TrabectedinMevastatin may increase the myopathic rhabdomyolysis activities of Trabectedin.Approved, Investigational
TramadolThe serum concentration of Mevastatin can be increased when it is combined with Tramadol.Approved, Investigational
TranilastThe risk or severity of adverse effects can be increased when Mevastatin is combined with Tranilast.Approved, Investigational
TranylcypromineThe serum concentration of Mevastatin can be increased when it is combined with Tranylcypromine.Approved
TroglitazoneThe serum concentration of Mevastatin can be increased when it is combined with Troglitazone.Investigational, Withdrawn
TroleandomycinThe serum concentration of Mevastatin can be increased when it is combined with Troleandomycin.Approved
TromethamineThe serum concentration of Mevastatin can be decreased when it is combined with Tromethamine.Approved
TylosinThe risk or severity of adverse effects can be increased when Tylosin is combined with Mevastatin.Vet Approved
Valproic AcidThe serum concentration of Mevastatin can be increased when it is combined with Valproic Acid.Approved, Investigational
VenlafaxineThe serum concentration of Mevastatin can be increased when it is combined with Venlafaxine.Approved
VerapamilThe risk or severity of adverse effects can be increased when Mevastatin is combined with Verapamil.Approved
VinblastineThe serum concentration of Mevastatin can be increased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Mevastatin can be increased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Mevastatin can be increased when it is combined with Vinorelbine.Approved, Investigational
VinpocetineThe risk or severity of adverse effects can be increased when Mevastatin is combined with Vinpocetine.Investigational
VoriconazoleThe serum concentration of Mevastatin can be increased when it is combined with Voriconazole.Approved, Investigational
WarfarinMevastatin may increase the anticoagulant activities of Warfarin.Approved
XylometazolineThe risk or severity of adverse effects can be increased when Mevastatin is combined with Xylometazoline.Approved
ZafirlukastThe serum concentration of Mevastatin can be increased when it is combined with Zafirlukast.Approved, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Mevastatin is combined with Ziconotide.Approved
ZiprasidoneThe serum concentration of Mevastatin can be increased when it is combined with Ziprasidone.Approved
ZolpidemThe serum concentration of Zolpidem can be increased when it is combined with Mevastatin.Approved
ZucapsaicinThe serum concentration of Mevastatin can be increased when it is combined with Zucapsaicin.Approved
Food Interactions
  • avoid alcohol
  • Grape fruit juice increases blood levels of the drug

References

Synthesis Reference

Scott Primrose, David King, Ed Yaworski, Jayaramaiyer Radhakrishnan, David He, Xinfa Xiao, "Fermentation process for preparation of compactin." U.S. Patent US5691173, issued September, 1977.

US5691173
General References
  1. Chemspider [Link]
  2. Pubchem [Link]
External Links
KEGG Compound
C13963
PubChem Compound
64715
PubChem Substance
99443247
ChemSpider
58262
BindingDB
50011036
ChEBI
34848
ChEMBL
CHEMBL54440
HET
2UO
Wikipedia
Mevastatin
PDB Entries
4oqr
MSDS
Download (350 KB)

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)152 °CPhysProp
logP3.95SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.0321 mg/mLALOGPS
logP4.13ALOGPS
logP3.62ChemAxon
logS-4.1ALOGPS
pKa (Strongest Acidic)14.91ChemAxon
pKa (Strongest Basic)-2.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area72.83 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity108.63 m3·mol-1ChemAxon
Polarizability43.57 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9714
Blood Brain Barrier+0.639
Caco-2 permeable-0.6631
P-glycoprotein substrateSubstrate0.7964
P-glycoprotein inhibitor INon-inhibitor0.8324
P-glycoprotein inhibitor IIInhibitor0.6601
Renal organic cation transporterNon-inhibitor0.8617
CYP450 2C9 substrateNon-substrate0.8503
CYP450 2D6 substrateNon-substrate0.9115
CYP450 3A4 substrateSubstrate0.7206
CYP450 1A2 substrateNon-inhibitor0.8952
CYP450 2C9 inhibitorNon-inhibitor0.8909
CYP450 2D6 inhibitorNon-inhibitor0.8903
CYP450 2C19 inhibitorNon-inhibitor0.8513
CYP450 3A4 inhibitorInhibitor0.6571
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7992
Ames testNon AMES toxic0.8927
CarcinogenicityNon-carcinogens0.9523
BiodegradationNot ready biodegradable0.8854
Rat acute toxicity2.6058 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8359
hERG inhibition (predictor II)Non-inhibitor0.6699
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as delta valerolactones. These are cyclic organic compounds containing an oxan-2- one moiety.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Lactones
Sub Class
Delta valerolactones
Direct Parent
Delta valerolactones
Alternative Parents
Fatty acid esters / Oxanes / Dicarboxylic acids and derivatives / Secondary alcohols / Carboxylic acid esters / Oxacyclic compounds / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Delta valerolactone / Fatty acid ester / Delta_valerolactone / Dicarboxylic acid or derivatives / Oxane / Fatty acyl / Carboxylic acid ester / Secondary alcohol / Carboxylic acid derivative / Oxacycle
Molecular Framework
Aliphatic heteropolycyclic compounds
External Descriptors
carboxylic ester, delta-lactone, carbobicyclic compound, statin (naturally occurring) (CHEBI:34848)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Nadph binding
Specific Function
Transmembrane glycoprotein that is the rate-limiting enzyme in cholesterol biosynthesis as well as in the biosynthesis of nonsterol isoprenoids that are essential for normal cell function including...
Gene Name
HMGCR
Uniprot ID
P04035
Uniprot Name
3-hydroxy-3-methylglutaryl-coenzyme A reductase
Molecular Weight
97475.155 Da
References
  1. Kocarek TA, Dahn MS, Cai H, Strom SC, Mercer-Haines NA: Regulation of CYP2B6 and CYP3A expression by hydroxymethylglutaryl coenzyme A inhibitors in primary cultured human hepatocytes. Drug Metab Dispos. 2002 Dec;30(12):1400-5. [PubMed:12433810]
  2. Cenedella RJ, Kuszak JR, Al-Ghoul KJ, Qin S, Sexton PS: Discordant expression of the sterol pathway in lens underlies simvastatin-induced cataracts in Chbb: Thom rats. J Lipid Res. 2003 Jan;44(1):198-211. [PubMed:12518039]
  3. Stoebner PE, Michot C, Ligeron C, Durand L, Meynadier J, Meunier L: [Simvastatin-induced lichen planus pemphigoides]. Ann Dermatol Venereol. 2003 Feb;130(2 Pt 1):187-90. [PubMed:12671581]
  4. Pappu AS, Bacon SP, Illingworth DR: Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia. J Lab Clin Med. 2003 Apr;141(4):250-6. [PubMed:12677170]
  5. Liu L, Zhang R, Zhao JJ, Rogers JD, Hsieh JY, Fang W, Matuszewski BK, Dobrinska MR: Determination of simvastatin-derived HMG-CoA reductase inhibitors in biomatrices using an automated enzyme inhibition assay with radioactivity detection. J Pharm Biomed Anal. 2003 Apr 24;32(1):107-23. [PubMed:12852453]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  7. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Triglyceride lipase activity
Specific Function
Involved in the detoxification of xenobiotics and in the activation of ester and amide prodrugs. Hydrolyzes aromatic and aliphatic esters, but has no catalytic activity toward amides or a fatty acy...
Gene Name
CES1
Uniprot ID
P23141
Uniprot Name
Liver carboxylesterase 1
Molecular Weight
62520.62 Da
References
  1. Fleming CD, Bencharit S, Edwards CC, Hyatt JL, Tsurkan L, Bai F, Fraga C, Morton CL, Howard-Williams EL, Potter PM, Redinbo MR: Structural insights into drug processing by human carboxylesterase 1: tamoxifen, mevastatin, and inhibition by benzil. J Mol Biol. 2005 Sep 9;352(1):165-77. [PubMed:16081098]

Drug created on March 13, 2010 15:07 / Updated on December 01, 2017 15:40